Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Emyria Ltd ( (AU:EMD) ) has provided an announcement.
Emyria Ltd has announced strategic leadership changes to support its anticipated growth, effective from January 22, 2025. Greg Hutchinson will become Executive Chairman, and Dr. Michael Winlo will transition to Chief Scientific Officer, focusing on research and drug discovery. These changes are aimed at scaling the company’s clinical services and strengthening its intellectual programs, positioning Emyria to meet increasing demand for mental health interventions.
More about Emyria Ltd
Emyria Ltd is a company involved in developing and delivering innovative treatments for mental health and select neurological conditions. The company focuses on unique care programs and new forms of therapy, including MDMA-assisted therapy for PTSD and psilocybin-assisted therapy for treatment-resistant depression.
YTD Price Performance: -11.76%
Average Trading Volume: 346,414
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$13.82M
Learn more about EMD stock on TipRanks’ Stock Analysis page.
